For the quarter ending 2025-10-31, ALZN made $998,109 in revenue. -$1,000,758 in net income. Net profit margin of -100.27%.
| Income Statement | 2025-10-31 | 2025-07-31 | ||
|---|---|---|---|---|
| Research and development | 176,283 | 1,740,867 | ||
| General and administrative | 821,826 | 959,334 | ||
| Total operating expenses | 998,109 | 2,700,201 | ||
| Loss from operations | -998,109 | -2,700,201 | ||
| Interest expense | 2,649 | 2,483 | ||
| Total other expense, net | -2,649 | -2,483 | ||
| Net loss | -1,000,758 | -2,702,684 | ||
| Net loss available to common shares | -1,000,758 | - | ||
| Basic net loss per common share | -0.3 | -1.28 | ||
| Basic weighted average common shares outstanding | 3,380,968 | 2,106,036 | ||
| Diluted net loss per common share | -0.3 | -1.28 | ||
| Diluted weighted average common shares outstanding | 3,380,968 | 2,106,036 | ||
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc. (ALZN)